Items tagged with Vaccines
Could a 100-year-old TB vaccine help scientists find a better one? (post)
Development of more effective TB drugs and vaccines is a pressing, unmet medical need.
T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection (post)
5 Jan 2023: Researchers from the South African Tuberculosis Vaccine Initiative (SATVI) have just published results from a study using cutting edge-technology to identify new targets for novel TB vaccine candidates.
An old TB vaccine might help stave off diabetes, cancer, Alzheimer’s, and more (post)
The bacillus Calmette-Guérin vaccine against tuberculosis—or simply BCG—is the oldest vaccine in the world that is still currently in use. Millions of infants in Africa and Asia receive the inoculation each year.
Study finds TB vaccines cost-effective in lower-income countries (post)
January 24, 2023 -- Harvard University researchers and collaborators conducted a modeling study that showed tuberculosis (TB) vaccination could be cost-effective in 73 of 105 (70%) low- and middle-income countries. The results, published on January 24 in PLOS Medicine, also predicted $474 billion in vaccine-related benefits by 2050.
TB vaccine does not protect elderly against COVID-19, finds large Dutch study (post)
The tuberculosis vaccine (or BCG vaccine) does not protect the elderly with co-morbidities against disease symptoms caused by a coronavirus infection. This was reported in the BCG-PRIME study which was initiated during the early days of the coronavirus pandemic when no vaccines against the virus were available. As a collaborative effort, the study was designed and conducted in a very short time in 20 Dutch hospitals led by UMC Utrecht. After the main findings were released in 2021, the full results of the study were published this week in Clinical Microbiology and Infection.
100 years of TB vaccine and yet the killer is still among us (post)
In 1921, the first effective tuberculosis (TB) vaccine was used on human subjects to help protect against this lethal disease. Yet, 100 years later in 2021, more than 1.6 million people died from TB across the world, according to the World Health Organization (WHO), making it the top killer infection once again. There is now an urgent need for new vaccine options to help stop this historical killer.
Temperature-stable TB vaccine safe, prompts immune response in NIH-supported study (post)
A clinical trial testing a freeze-dried, temperature-stable experimental tuberculosis (TB) vaccine in healthy adults found that it was safe and stimulated both antibodies and responses from the cellular arm of the immune system. The Phase 1 trial was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. A non-temperature stable form of the candidate previously had been tested in several clinical trials. However, this was the first clinical trial of any subunit TB vaccine candidate in a temperature-stable (thermostable) form. Results are published in Nature Communications.
Frozen cells reveal a clue for a vaccine to block the deadly TB bug (post)
Tuberculosis may seem like a relic of the past in wealthy countries, yet it still kills more people worldwide than any other infectious disease besides COVID – with about 1.6 million people dying from TB annually. And the one approved vaccine – invented more than a century ago – is only reliably protective when given to children.
TAG webinar: TB vaccine development: The next chapter starts now (post)
Treatment Action Group (TAG) will host a webinar on 13 April 2023 that will provide an overview of the TB vaccine pipeline, based on TAG’s recent Tuberculosis Vaccines Pipeline Report, including the different candidates at different stages of research, and ongoing and upcoming studies that advocates should closely follow.
New TB vaccines needed to tackle AMR (post)
Tuberculosis (TB) is an airborne global pandemic that kills 1.6 million people each year, causes over 10 million people to fall sick, and poses catastrophic costs for patients and rising costs for health systems. The growing threat of drug-resistant TB is a major contributor to the global burden of antimicrobial resistance (AMR) and a significant cause of AMR deaths. New vaccines are urgently needed to tackle this crisis. Yet, despite the huge threat posed by drug-resistant TB, political and financial support falls dangerously short of what is needed to effectively address this threat.
Page 22 of 32 · Total posts: 0
←First 21 22 23 Last→